Tian An Medicare (SEHK:383) Stock Trails Revenue Progress With Margin Squeeze

Tian An Medicare went into this earnings day with a flat week, a weak three month share price and a very expensive trailing P/E of 95.5x for a healthcare stock in Hong Kong. The market had already priced in a lot of hope. The headline from the half year numbers is margin strain. Trailing net profit margin has compressed to 0.5% and reported earnings still carry the weight of a HK$71.3m one off loss in the twelve months to 30 June 2026. Investors now have to judge whether that thin profitability can support such a rich valuation.

Is Tian An Medicare trading at a premium that thin margins and a recent HK$71.3m one off loss cannot justify, or is the market already looking past it? Compare the stock’s rich P/E with its earnings quality in the valuation analysis for Tian An Medicare

H1 2026 Earnings Summary

• Revenue, H1 2026 vs. H1 2025: HK$827.097m vs. HK$783.132m (change reflects higher reported revenue)
• Net Income, H1 2026 vs. H1 2025: HK$47.361m vs. HK$11.979m (change reflects higher reported net income)
• Basic EPS, H1 2026 vs. H1 2025: HK$0.0442 vs. HK$0.01105 (change reflects higher reported earnings per share)
• Trailing 12-Month Net Profit Margin, to 30 June 2026 vs. prior year: 0.5% vs. 1.2% (margin compressed over the period)

Tired of wading through dense earnings reports and tiny margin figures for Tian An Medicare? Get a clear visual snapshot of the company’s valuation and how the current P/E lines up with its fundamentals in the company report for Tian An Medicare.

Revenue Growth Gives Tian An Medicare Some Support

For Tian An Medicare, the latest figures give bulls one clear talking point. Revenue for H1 2026 is higher than H1 2025 and net income and basic EPS are also higher over the same period. That fits the idea of a healthcare and eldercare platform that is at least moving forward in absolute earnings. For investors who like the demographic story, these numbers show the core business can still produce profit, even if the margin on that profit is slim.

Margin Compression Keeps The Cautious Case In Play

The cautious view on Tian An Medicare also finds support in these results. Trailing 12 month net profit margin has compressed from 1.2% to 0.5% and recent earnings still include a HK$71.3m one off loss. That keeps questions alive about earnings quality and the resilience of such thin profitability. The weak 90 day share price performance, with the stock down roughly 23%, suggests the market has been treating these risks seriously even before the latest numbers.

After a 23% share price decline, thin 0.5% margins and one off hits, review whether Tian An Medicare faces deeper structural issues in the risk analysis for Tian An Medicare which shows 3 important warning signs.

Take Control Of Your Next Move

If Tian An Medicare's thin 0.5% margins and rich 95.5x P/E have your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch for a better entry point. Once you own it or any other stock, use the Portfolio Command Center to cut through noise and focus on the key developments that matter to your holdings. For a longer term view, tap into crowd insights and different angles on Tian An Medicare and other companies through the Community. This way you can spot potential catalysts and risks earlier and stay a step ahead of the market.

Seeking Alternatives Beyond Tian An Medicare?

Fresh ideas can get caught in a breakout or lose momentum fast. Scan these under the radar picks before the crowd catches on and the best entry points start dropping, act now.

• Spot potential early movers with solid balance sheets and steady fundamentals by scanning the curated list of solid balance sheet and fundamentals stocks (435 results)
• Chase income opportunities by reviewing hand picked companies known for robust payouts through the focused 442 dividend fortresses
• Hunt for under followed stocks that still show strong financial quality using the carefully filtered 618 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com